AI Research Summary
Health investors demand clinical evidence of outcomes, not just adoption metrics, because payers are structurally moving toward value-based care—making outcomes the actual business model. Founders who raise serious rounds in digital health build their data architecture and define clinical endpoints before acquiring their first patient, while those who defer this work end up in diligence meetings defending evidence that doesn't hold up.
Article Snapshot
At-a-glance research context
| Content Category | Impact Investing |
| Target Reader | Health startup founders, impact investors |
| Key Data Point | $10.7B digital health funding in 2023; evidence, not pitch, wins capital |
| Time to Apply | Ongoing |
| Difficulty Level | Advanced |
Digital health venture funding reached $10.7 billion in 2023, according to Rock Health's Annual Digital Health Funding Report [1]. The number sounds large until you understand the selection process: health investors are among the most demanding in venture capital, and the bar for what constitutes fundable evidence has risen substantially.
I've talked with enough health impact founders to know where the gap is. It's not usually the idea. It's not usually the market. It's the data. Founders who don't build their data architecture from day one end up in diligence meetings trying to retrospectively justify clinical claims with evidence that doesn't hold up.
The founders who raise serious rounds in health impact have typically built their evidence strategy before they built their product.
Why Health Impact Investors Are More Demanding
The health investment thesis has a specific structure that explains the evidence bar:
Health investors are betting that a product or service will produce measurable health outcomes — not just that patients will use it or pay for it, but that clinical markers will improve, hospitalizations will be avoided, or disease progression will slow. The commercial model depends on payers (insurers, employers, government) paying for demonstrated outcomes.
This is fundamentally different from consumer app investing, where adoption and engagement are the primary metrics. In health, adoption without outcomes is a failed product.
The demand for outcomes evidence flows from the payer economics: Medicare, Medicaid, and commercial insurers are all moving toward value-based care — payment models that reward outcomes rather than procedures [2]. A health startup that can't demonstrate outcomes can't access value-based payment contracts, which means it's dependent on fee-for-service revenue from a payer system that's structurally evolving away from fee-for-service.
If you can't show clinical outcomes, you're building a consumer health app, not a health impact company. The distinction matters to investors, to payers, and ultimately to the patients you're claiming to serve.
The Data Architecture of a Fundable Health Impact Company
Founders who are serious about raising venture capital for health impact companies should make several data architecture decisions before they acquire their first patient:
Define primary and secondary endpoints. A clinical endpoint is a measurable outcome that determines whether your intervention worked. Primary endpoints are the main clinical measure you're optimizing for; secondary endpoints are related measures that provide supporting evidence. Investors will ask what your endpoints are and how you're measuring them. Having vague answers to this question is disqualifying in health investing.
Build for HIPAA compliance from the start. Health data has specific regulatory requirements that impose both cost and capability requirements [3]. Building a data system that isn't HIPAA compliant from the first patient is a liability that compounds — retrospectively complying is significantly more expensive and time-consuming than building right initially.
Instrument for real-world evidence. The most fundable health companies generate real-world evidence: clinical outcomes data collected from actual patients in actual care settings, not just from randomized controlled trials. Real-world evidence data requires investment in measurement infrastructure — outcome surveys, connected device integration, EHR integration, lab data — that many founders defer because it's expensive. Don't defer it.
Track disaggregated outcomes. Health equity is increasingly a fundable dimension of health impact. Investors and payers are asking whether your intervention produces equivalent outcomes across demographic subgroups — by race, income, language, and geography. If you're not collecting disaggregated data from the beginning, you can't answer this question, and increasingly you won't be able to access certain payers and contracts that require evidence of equity.
The Evidence Hierarchy Health Investors Use
Health investors evaluate evidence on an implicit hierarchy:
Randomized controlled trials are the gold standard. RCTs with peer-reviewed publication are the highest quality evidence for a specific clinical claim. They're expensive, time-consuming, and often not feasible in the early stages. Investors don't usually expect them at seed stage, but companies that have RCT evidence have a significant fundraising advantage at growth stage.
Prospective observational studies — tracking outcomes in a defined patient population over time, with a comparison group — are achievable earlier and at lower cost than RCTs. They provide real-world evidence of clinical impact without randomization.
Retrospective analyses — looking back at patient data to identify outcomes patterns — are the most common early-stage evidence type but the least compelling. Investors understand that retrospective studies have selection bias and confounding; a retrospective analysis is a starting point, not a conclusion.
Engagement and utilization data — patients are using the product, completing programs, returning — is necessary but not sufficient. Investors will ask what outcomes are associated with engagement. Engagement data alone doesn't answer the clinical question.
The GIIN's 2024 research identifies healthcare as one of the two largest impact investment categories [4]. The measurement standards in health impact are more mature than most other impact categories, primarily because clinical outcomes measurement has decades of methodology development behind it.
The Payer Evidence Standard vs. The Investor Evidence Standard
An important distinction: the evidence standard for convincing health investors and the evidence standard for convincing payers are related but different.
For investors, the primary question is whether you have evidence that your product produces clinical outcomes — and whether that evidence is strong enough to support the commercial thesis. Seed-stage investors might accept strong pilot data; Series B investors typically want published peer-reviewed evidence or a robust real-world evidence dataset.
For payers, the standard is increasingly outcomes-based contracts — where the payer pays for demonstrated patient outcomes rather than for service utilization. To access outcomes-based contracts, you need clinical evidence (demonstrating what outcomes to measure) and data infrastructure (demonstrating how you'll measure and report them in live deployments).
Founders who build their evidence strategy around the payer standard — what do I need to prove to get an outcomes-based contract? — are building toward fundable evidence rather than optimizing for investor validation alone.
What the First 100 Patients Should Prove
For pre-seed or seed-stage health impact founders, the first 100 patients are a research study as much as a commercial deployment.
Define the questions before you start: what clinical hypothesis are you testing? What outcome measures will you collect? What comparison point will you use (pre-intervention baseline, published benchmark, or wait-list control)?
Build the measurement infrastructure before you acquire patients — the survey cadence, the data collection system, the analysis framework. Retrofitting measurement infrastructure onto an existing patient population produces lower-quality evidence than building it correctly from the start.
Report honestly what you find. The founders who raise follow-on funding are not the ones who only report positive outcomes — they're the ones who can honestly characterize what their intervention does and doesn't do, for which patients, in which contexts. That granularity is more fundable than a single top-line positive result.
Related Reading
- Outcome-Based Health Contracts: Can Investors Get Paid for Better Patient Outcomes?
- Telehealth and Beyond: Building Venture-Backed Models for Affordable, Inclusive Care
The Bottom Line
Digital health investing rewards clinical evidence, not compelling pitches. The founders who raise serious rounds have built their evidence architecture before their first patient: defined clinical endpoints, HIPAA-compliant data systems, real-world evidence instrumentation, and disaggregated outcome tracking for health equity. The evidence hierarchy investors use — RCTs, prospective observational studies, retrospective analyses, engagement data — maps directly to the evidence standard payers use for outcomes-based contracts. Building toward the payer evidence standard is building toward fundable evidence. The first 100 patients are a research study: define the hypothesis first, build the measurement infrastructure before acquisition, report honestly on what you find.
FAQ
What is a health impact startup?
A health impact startup is a company that builds a product or service designed to produce measurable health outcomes — such as improved clinical markers, avoided hospitalizations, or slowed disease progression — rather than just achieving user adoption. Health impact startups differ from consumer health apps because they're designed to access value-based payment contracts with payers like Medicare, Medicaid, and commercial insurers who pay for demonstrated clinical outcomes.
Why does health impact startup funding matter for side hustlers and aspiring founders?
Health impact startups represent one of the largest investment categories available to founders, with $10.7 billion raised in digital health in 2023 alone, according to Rock Health's Annual Digital Health Funding Report [1]. However, the bar for funding is exceptionally high — investors require clinical evidence of outcomes from day one, which means founders who understand how to build evidence architecture before building their product have a significant competitive advantage in accessing serious venture capital.
How do you build a data architecture for a fundable health impact startup?
Build your data architecture before acquiring your first patient by defining primary and secondary clinical endpoints, achieving HIPAA compliance from the start [3], instrumenting for real-world evidence collection (outcome surveys, connected devices, EHR integration), and tracking disaggregated outcomes across demographic subgroups. Founders who defer this work end up in fundraising meetings trying to retrospectively justify clinical claims with evidence that doesn't hold up.
How much funding can you raise for a health impact startup?
Digital health companies raised a total of $10.7 billion in 2023 [1], with most capital flowing to companies that could demonstrate clinical evidence, not just compelling pitches. The amount you can raise depends on your evidence strength — companies with randomized controlled trial evidence or prospective observational studies have significantly higher fundraising valuations at growth stage than those relying only on retrospective analyses or engagement data.
What are the risks of building a health impact startup without proper data infrastructure?
Building without proper data infrastructure creates compounding liabilities: you can't demonstrate clinical outcomes to investors or payers, you become dependent on fee-for-service revenue from a payer system structurally evolving away from it [2], and retrospectively achieving HIPAA compliance is significantly more expensive and time-consuming than building compliant systems initially [3]. Additionally, without disaggregated outcome data, you'll lose access to payers and contracts increasingly requiring evidence of health equity.
How do you get started founding a health impact startup?
Define your primary and secondary clinical endpoints before you acquire your first patient, then build your data infrastructure to measure those outcomes with HIPAA compliance, real-world evidence collection tools, and disaggregated tracking across demographic groups. The founders who raise serious rounds in health impact have typically built their evidence strategy before they built their product — not after.
What percentage of digital health funding in 2023 went to companies demonstrating clinical evidence?
The exact percentage isn't specified in available data, but Rock Health's 2023 Annual Digital Health Funding Report [1] confirms that the vast majority of the $10.7 billion in digital health venture funding went to companies that could demonstrate clinical evidence, not just compelling pitches. This indicates that clinical evidence is now a prerequisite for accessing serious venture capital in health impact.
References
- Rock Health. (2023). Annual Digital Health Funding Report. Rock Health
- Centers for Medicare & Medicaid Services. (2024). Value-Based Care Programs. CMS
- U.S. Department of Health & Human Services. Health Insurance Portability and Accountability Act (HIPAA). HHS
- Global Impact Investing Network. (2024). Sizing the Impact Investing Market. GIIN
